BELLICUM PHARMACEUTICALS INC's ticker is BLCM and the CUSIP is 079481107. A total of 102 filers reported holding BELLICUM PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 0.33 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $13,000 | +18.2% | 3,781 | 0.0% | 0.00% | – |
| Q4 2018 | $11,000 | -52.2% | 3,781 | 0.0% | 0.00% | – |
| Q3 2018 | $23,000 | -17.9% | 3,781 | 0.0% | 0.00% | – |
| Q2 2018 | $28,000 | -37.8% | 3,781 | -44.6% | 0.00% | – |
| Q1 2018 | $45,000 | -67.4% | 6,831 | -58.3% | 0.00% | -100.0% |
| Q4 2017 | $138,000 | -27.0% | 16,370 | 0.0% | 0.00% | -50.0% |
| Q3 2017 | $189,000 | -13.7% | 16,370 | -7.9% | 0.00% | 0.0% |
| Q1 2017 | $219,000 | -10.6% | 17,770 | -1.0% | 0.00% | -33.3% |
| Q4 2016 | $245,000 | -88.3% | 17,957 | -82.9% | 0.00% | -86.4% |
| Q3 2016 | $2,092,000 | +54.5% | 105,126 | +0.6% | 0.02% | +22.2% |
| Q2 2016 | $1,354,000 | +43.9% | 104,509 | +3.9% | 0.02% | +50.0% |
| Q1 2016 | $941,000 | -34.1% | 100,621 | +42.8% | 0.01% | -33.3% |
| Q4 2015 | $1,428,000 | +46.0% | 70,454 | +4.6% | 0.02% | +28.6% |
| Q3 2015 | $978,000 | +192.8% | 67,343 | +328.9% | 0.01% | +180.0% |
| Q2 2015 | $334,000 | +37.4% | 15,702 | +49.5% | 0.01% | +66.7% |
| Q1 2015 | $243,000 | – | 10,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Avoro Capital Advisors LLC | 220,000 | $5,069,000 | 3.43% |
| Perceptive Advisors | 1,046,402 | $24,109,000 | 2.02% |
| Redmile Group, LLC | 860,809 | $17,269,000 | 1.88% |
| Baker Brothers Advisors | 4,283,732 | $98,697,000 | 1.01% |
| RA Capital Management | 1,026,402 | $9,337,000 | 1.00% |
| Ghost Tree Capital, LLC | 75,000 | $1,728,000 | 0.83% |
| ACUTA CAPITAL PARTNERS, LLC | 45,750 | $1,054,000 | 0.71% |
| GREAT POINT PARTNERS LLC | 50,000 | $1,152,000 | 0.55% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 167,210 | $3,853,000 | 0.33% |
| EMERALD ADVISERS, LLC | 198,202 | $4,567,000 | 0.24% |